5 Best Biotech Bets Likely To Outperform Estimates In Q4

How to Pick Probable Q4 Winners?

There are multiple drug/biotech companies poised to beat on fourth-quarter earnings. However, given the large number of drug/biotech firms, the task of selecting stocks with possibilities to surpass expectations could appear quite daunting.

With the help of the Zacks Stock Screener, we have zeroed in on five drug/ biotech stocks that carry a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) and a positive Earnings ESP. It is a valuable tool for investors looking for stocks with the maximum potential to beat estimates. Our research shows that with this combination, chances of a positive surprise are as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

5 Stocks Set to Surpass Mark

Celgene Corporation (CELG - Free Report) has an Earnings ESP of +2.31% and a Zacks Rank of 1. The Zacks Consensus Estimate for fourth-quarter 2018 is pegged at $2.32. The company has a trailing four-quarter average positive surprise of 2.54%. It is expected to report on Jan 24.

Regeneron Pharmaceuticals Inc. (REGN - Free Report) has an Earnings ESP of +6.12% and a Zacks Rank #3. The Zacks Consensus Estimate for fourth-quarter 2018 earnings stands at $5.68. The company’s earnings topped estimates in the last four reported quarters, the average being 10.97%. The company is slated to release earnings on Feb 14, before the market opens.

Amgen Inc. (AMGN - Free Report) has an Earnings ESP of +0.25% and a Zacks Rank of 3. The Zacks Consensus Estimate for fourth-quarter 2018 is projected at $3.26. The company’s earnings trumped estimates in three of the preceding four reported quarters, the average earnings surprise being 4.80%. It is scheduled to announce earnings numbers on Jan 29 after market close.

Alnylam Pharmaceuticals Inc. (ALNY - Free Report) )has an Earnings ESP of +1.65% and is a Zacks #3 Ranked player. The consensus estimate for the fourth-quarter bottom line is pegged at a loss of $1.97. The company is anticipated to report earnings on Feb 14.

View single page >> |

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.